Takeda has announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the ...
Investor's Business Daily on MSN
Zeta Global Holdings earns membership in 95-plus composite rating club
On Monday, Zeta Global Holdings ZETA got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. Please watch the ...
Caldera Therapeutics, Inc. (Caldera), a clinical stage biotechnology company developing the first-in-class bispecific ...
In addition, $14B Mather Group acquires a New Jersey-based firm, Prime Capital recruits an established RPA, and EY analysts ...
International study of microbiome data finds loss of beneficial bacteria and increase in bacteria from mouth lower in the gut ...
Investor's Business Daily on MSN
TD SYNNEX sees relative strength rating rise to 73
TD SYNNEX SNX saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 64 to 73.
Pharmaceutical Technology on MSN
JPM26: J&J leans on immunology launches to fuel annual growth
Tremfya and Icotide are touted as key growth drivers in J&J’s strongly performing innovative medicines business.
According to DataM Intelligence, the global Inflammatory Diseases Biologics Market was valued at USD 99.06 billion in 2024 and is projected ...
Cambridge, USA-based clinical-stage biotechnology company Caldera Therapeutics, which is developing the first-in-class ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Halozyme Therapeutics Inc. has entered into a global collaboration and exclusive license agreement with Takeda.
Dr Ray O’Connor takes a look at recent clinical articles on Diet and GI Issues, including the effects of caffeine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback